2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5234 Daraxonrasib sensitizes RAS-mutant KMT2A-rearranged AML to menin inhibition

Julia Dudkiewicz-Garbicz, MD, Aishwarya Ballapuram2, Wallace A. Bourgeois, MD3, Ella Haney4, Filip Garbicz, MD, PhD5, Anushka Walia, MD6, Jeevitha D'Souza, Postdoctoral fellow7, Abigail S. Lin8, Alexa Rane Batingana9, Todd A. Alonzo, PhD10, Robert B. Gerbing, Ph.D11, Rhonda E. Ries, MA12, Jack H. Peplinski, MSc13, Li Fan, PhD14, Nastassja Scheidegger, MD15, Denise Masli16, Camille Leung, BS, BA17, Alan S. Gamis, MD18, Richard Aplenc I, MD, PhD19, Todd Cooper I, DO20, Katherine Tarlock I, MD21, Xiaotu Ma, PhD22, Ruben D. Carrasco, MD23, Kimberly Stegmaier, MD24, Kevin Shannon, MD25, Scott A Armstrong, MD, PhD26, Soheil Meshinchi, MD, PhD27, Benjamin J. Huang, MD28, Yana Pikman, MD29
1 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 University of California San Francisco, San Francisco, California, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 University of California San Francisco, San Francisco, California, United States
7 University of California San Francisco, San Francisco, California, United States
8 University of California San Francisco, San Francisco, California, United States
9 University of California San Francisco, San Francisco, California, United States
10 University of Southern California, Los Angeles, California, United States
11 Children's Oncology Group, Arcadia, California, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States
14 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, University Children's Hospital Zurich, Zurich, Switzerland
16 University of California San Francisco, San Francisco, California, United States
17 University of California San Francisco, San Francisco, California, United States
18 Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States
19 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
20 Seattle Children’s Hospital, Seattle, Washington, United States
21 Seattle Children’s Hospital, Seattle, Washington, United States
22 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
23 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
24 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
25 University of California San Francisco, San Francisco, California, United States, University of California San Francisco, San Francisco, California, United States
26 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
27 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children’s Hospital, Seattle, Washington, United States
28 University of California San Francisco, San Francisco, California, United States, University of California San Francisco, San Francisco, California, United States
29 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Approximately 10% of all acute leukemias harbor a chromosomal translocation involving the lysine methyltransferase 2A (MLL1/KMT2A) gene locus with over 100 fusion partners. KMT2A fusion proteins associate with a menin-containing chromatin complex that drives an aberrant oncogenic gene-expression program leading to a highly aggressive leukemia with a poor prognosis. These fusions are especially prevalent in pediatric acute myeloid leukemia (AML), where KMT2A rearrangements (KMT2A-r) are present in about 20% of patients. Small-molecule menin inhibitors that disrupt this KMT2A transcriptional complex have transformed the treatment paradigm for KMT2A-r leukemia, with the menin inhibitors revumenib and ziftomenib recently FDA-approved for relapsed/refractory KMT2A-r or NPM1-mutant AML. However, in early trials about 50% of AML failed to respond to revumenib alone. Patients with leukemia that did respond to revumenib rapidly developed resistance to single agent treatment, underscoring the need for effective combinations.

RAS pathway mutations, involving the genes NRAS, KRAS, and PTPN11, are among the most frequent alterations co-occurring with KMT2A-r, present in 51% of pediatric KMT2A-r AML, and are associated with lower complete remission rates, inferior event-free survival, and early relapse. RAS mutations confer resistance to other targeted agents, including venetoclax and FLT3 inhibitors. We hypothesized that the combination of targeting RAS signaling with menin inhibition would be synergistic in KMT2A-r RAS-mutant AML.

We first evaluated revumenib sensitivity in 6 KMT2A-r AML cell lines differing in RAS status (RAS-mutant vs. RAS-wild-type) and an isogenic NRAS G12D doxycycline-inducible KMT2A-r MOLM13 AML model.  Expression of mutant  NRAS or KRAS decreased sensitivity to menin inhibitors compared to RAS-wild-type KMT2A-r cells, including in a doxycycline-induced NRAS expression level dependent manner. Daraxonrasib (RMC-6236) is a potent, oral inhibitor of wild-type and mutant GTP-bound RAS that blocks the RAS-effector interactions required for oncogenic signaling.  Daraxonrasib decreased growth of three AML cell lines harboring KMT2A::MLLT3 or NPM1 with co-occurring NRAS or KRAS mutations. In isogenic AML cell lines, cells expressing NRAS or KRAS G12X mutations were more sensitive to daraxonrasib compared to cells with NRAS or KRAS Q61X mutations. Treatment with daraxonrasib resulted in rapid apoptosis at low nanomolar concentrations. Co-treatment with daraxonrasib and revumenib in RAS-mutant AML cell lines decreased cell viability and increased apoptosis. Daraxonrasib induced a mild G0/G1 cell cycle arrest with an increased subG1 (cell death) fraction, further potentiated by co-treatment with revumenib. Daraxonrasib and menin inhibition each reduced phosphorylated ERK (pERK) levels, with a stronger effect on pERK with the combination.

We then tested the combination of revumenib with daraxonrasib in a highly aggressive patient-derived xenograft (PDX) AML model characterized by KMT2A::PICALM rearrangement and NRAS p.Q61L. NSG mice engrafted with the PDX model via tail vein injection were assigned to four treatment groups: vehicle (n=8), daraxonrasib (25mg/kg every other day; n=8), revumenib chow (0.033%; n=8), or the combination (n=8). Bone marrow, spleen and peripheral blood leukemia burden were assessed by flow cytometry after 10 days of treatment in 4 mice per group. There was a decrease in pERK by IHC after single-agent revumenib or daraxonrasib treatment that was further decreased in the combination, confirming on-target activity. There was a significant decrease in the mean bone marrow, spleen, and peripheral blood leukemia burden in single-arm treated mice that was potentiated in the combination treatment as measured by %hCD45+ (p<0.001). The remaining mice completed a total of 14 days of treatment and were followed for survival. The median survival was significantly prolonged with the combination treatment (vehicle: 38 days, daraxonrasib: 53 days, revumenib: 128 days, and combination: not reached)(p<0.001).

In conclusion, our data indicate that daraxonrasib enhances response to revumenib in RAS-mutant KMT2A-r AML, addressing a key limitation of single-agent menin inhibition, and provides strong preclinical rationale for clinical investigation of this combination in high-risk, RAS-mutant KMT2A-r AML.

Julia Dudkiewicz-Garbicz, MD: No relevant conflicts of interest to declare.